louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05344586: The Effects of Hamstring Stretching With and Without Neural Load on Flexibility, Maximum Isometric Strength and Tibial Nerve Pressure Pain Threshold
Official title: The Effects of Neural Load on Hamstring Stretching Upon Range of Motion, Maximum Isometric Strength and Tibial Nerve Pressure Pain Threshold in Asymptomatic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: University of Jaén
Sponsor class: OTHER
First posted: 2022-04-25
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will be carried out at the Faculty of Nursing and Physiotherapy of the University of Alcala. The study has been approved by the Animal Research and Experimentation Ethics Committee of the University of Alcalá. Healthy subjects will be recruited and divided into two groups randomly to perform a hamstring stretching program for two months.

One group will perform a stretch with neural load and the other without neural load, although both groups will stretch for the same amount of time, repetitions and subjective sensation.

Participants will be measured before and after performing their assigned stretch. Then, a new post-stretch measurement will be taken after two months, period during which the subjects will perform the stretching program on their own. Finally, subjects will be asked to quit the stretching program to take a final evaluation measurement after one month of follow-up.

The objective will be to evaluate the effects of stretching with and without neural load on hamstring flexibility (main variable), maximum isometric strength and tibial nerve pressure pain threshold.


Eligibility criteria: Inclusion Criteria:

* Healthy subjects who do not perform hamstring stretches with neural load in their daily training routine

Exclusion Criteria:

* Elite athletes competing or preparing for competition
* Lower limb surgery
* Hamstring injury in the last year
* Neurological, rheumatologic and/or orthopedic pathological history of lower limbs.
* Other comorbidities

Primary outcomes:
measure: Changes in hamstring flexibility
timeFrame: Baseline, 2 months and 3 months after intervention commencement
Secondary outcomes:
measure: Changes in maximum isometric hamstring strength
timeFrame: Baseline, 2 months and 3 months after intervention commencement
Other outcomes:
measure: Changes on tibial nerve pressure pain threshold
timeFrame: Baseline, 2 months and 3 months after intervention commencement
Locations:
city: Alcalá De Henares
country: Spain
facility: Juan
state: Madrid
Study officials:
affiliation: University of Alcalá, Madrid, Spain
name: Juan Mínguez
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06804486: Exercise and Physical Activity in Children with Pediatric Acquired Brain Injury
Official title: Exercise and Physical Activity in Children with Pediatric Acquired Brain Injury
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Acquired Brain Injury
Keywords: PEDIATRIC ACQUIRED BRAIN INJURY
exercise
physical-sports activity
intervention
Lead sponsor: Universidade da Coruña
Sponsor class: OTHER
First posted: 2025-02-03
Enrollment: 25
Sex: ALL
Minimum age (years): 7
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Exercise and physical activity in children with pediatric acquired brain injury

Detailed description: Although emerging approaches have emerged in the design of interventions that promote an orientation towards physical activity scientific evidence on their efficacy in this particular population remains limited. This underscores the need for further research to evaluate the efficacy of these intervention approaches in the context of pediatric ABI.

Eligibility criteria: Inclusion Criteria:

* Be under 18 years of age and present a medical diagnosis of pediatric acquired brain injury.
* Have the informed consent completed and signed
* Present a state that allows following indications for the practice of exercise and physical-sports activity.

Exclusion Criteria:

* Have medical comorbidities that contraindicate the safe performance of the program (i.e., cardiac or respiratory instability, uncontrolled seizures).
* Have additional disabling conditions, such as cognitive impairment and/or an inability to communicate with the researcher verbally, in writing, or through an emissary.
* Non-attendance and/or non-collaboration at 70% of the sessions of the program.

Primary outcomes:
measure: Quality of Life
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
measure: Functionality
timeFrame: Through study completion, an average of 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02493686: Age Dependence of Audiometric Bone Conduction Threshold in Normal Hearing Subjects
Official title: Age Dependence of Audiometric Bone Conduction Threshold in Normal Hearing Subjects
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Air Bone Gap
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2015-07-09
Enrollment: 1093
Sex: ALL
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Persons which have a normal hearing threshold level in the airconduction.

Brief summary: Examination of the bone conduction of persons which according to the pure tone audiogram have a normal age related hearing threshold in the air conduction.


Eligibility criteria: Inclusion Criteria:

* All pure tone audiograms recorded and available in the system from the beginning of measurement as follows:
* age related normal hearing threshold level with air conducted pure tone audiogram

Exclusion Criteria:

* age younger than 20 years
* if inclusion criteria not given

Primary outcomes:
measure: Bone conduction Threshold/ Air bone gap in normal hearing subject in relation to age
timeFrame: 1960 - 2014 (54 years)
Secondary outcomes:
measure: Air bone gap changes in individuals who have received more than one Audiogram
timeFrame: 1960 - 2014 (54 years)
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital Zurich, clinic othorhinolaryngology, 8091 Zurich
name: Rudolf Probst, Prof.
role: STUDY_DIRECTOR
References:
Clinical trial NCT01314586: Flax Lignans and Heart Health
Official title: Iowa State Study on Flax Lignans and Heart Health
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypercholesterolemia
Keywords: hypercholesterolemia
postmenopause
secoisolariciresinol diglucoside
flaxseed
lignans
enterolactone
enterodiol
serum cholesterol
LDL cholesterol
Lead sponsor: Iowa State University
Sponsor class: OTHER
Collaborators: name: Archer Daniels Midland Co.
First posted: 2011-03-14
Enrollment: 93
Sex: ALL
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Purpose: To demonstrate the efficacy of Beneflax™ flaxseed lignan (SDG) concentrate to lower serum cholesterol levels.

Background: Flaxseed has been studied for various health benefits in humans, including prostate health, glucose control, and cardiovascular health. Cholesterol levels and high blood pressure are known to be risk factors for cardiovascular disease. Whole flaxseed has had variable effects on serum lipid levels, perhaps a consequence of variations in the amounts of secoisolariciresinol diglucoside (SDG) found in different flax cultivars, making the study of this bioactive compound difficult.

Hypothesis: Flaxseed lignan (SDG) extract (Beneflax) significantly lowers total and LDL cholesterol. Flaxseed lignans also lower blood pressure and fasting glucose levels.


Eligibility criteria: Inclusion Criteria:

* Men, 40-65 yrs/old, postmenopausal women 50-65 yrs/old not \> 5 yrs post menopause. All subjects were hypercholesterolemic with either total cholesterol \>240 mg/dl and \< 320 mg/dL or LDL cholesterol \>140 mg/dl and \<190 mg/dl at the screening visit.

Exclusion Criteria:

* Excluded subjects included diabetics, people being actively treated with niacins, fibrates, statins, insulin, ACE inhibitors or other cholesterol/ blood pressure pharmaceutical treatments, people who consumed large amounts of soy, flax, rye breads, pumpkin seeds, hydrolyzed milk products, sterols, and/or berries (strawberries/blueberries) or supplements aimed at cholesterol reduction such as spruce lignans, sytrinol (poly methoxylated flavanols), polycosinols, people consuming flaxseed on a regular basis.

Primary outcomes:
measure: Change in serum total cholesterol from baseline to 12 weeks after intervention treatments
timeFrame: 12 weeks
measure: Change in serum glucose from baseline to 12 weeks after intervention treatments
timeFrame: 12 weeks
measure: Change in blood pressure from baseline to end of treatment
timeFrame: 12 weeks
Secondary outcomes:
measure: Changes in serum clinical chemistry from baseline to end of treatment
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Ames
country: United States
facility: Nutrition & Wellness Research Center
state: Iowa
Study officials:
affiliation: Iowa State University
name: Suzanne Hendrich, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04935086: Risk Factors for Predictors of MACEs After RA-CABG
Official title: Risk Factors for Predictors of Major Adverse Cardiovascular Events After Coronary Artery Bypass Using Radial Artery Grafts
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Keywords: Risk Factors
CABG
Radial Artery
MACE
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
First posted: 2021-06-22
Enrollment: 370
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients 18-year and above underwent RA-CABG from Jan. 2009 to Dec.2019 in one single center.

Brief summary: As the secondary choice of artery grafts, radial artery is more and more used to achieve multiple arterial revascularization in CABG. Risk factors for predictors of major cardiovascular adverse events (MACE) after CABG using radial-artery grafts (RA-CABG), however, remain uncertain. This case-control study aims to identify the baseline predictors of MACE after RA-CABG.

We will collect the baseline characteristics and perioperative data of patients underwent RA-CABG from Jan. 2009 to Dec. 2019 in our single center. By reviewing the latest follow-up records, we will examine the correlation between the baseline characteristics and clinical outcomes (MACEs), then identify the independent risk factors for predictors of MACEs after RA-CABG.


Eligibility criteria: Inclusion Criteria:

* Underwent CABG using at least a radial artery grafts from Jan.2009 to Dec.2019. with or without cardiopulmonary bypass , with or without concomitant procedure
* Aged 18 and above at procedure
* With any gender

Exclusion Criteria:

* With unavailable medical records

Primary outcomes:
measure: 7-day MACE-4
timeFrame: 7 days post-CABG
measure: 30-day MACE-4
timeFrame: 30 days post-CABG
measure: 1-year MACE-4
timeFrame: 1 year post-CABG
measure: 3-year MACE-4
timeFrame: 3 years post-CABG
Secondary outcomes:
measure: MACE-3
timeFrame: 7 days, 30 days, 1 year, and 3 years post-CABG
measure: All-cause death
timeFrame: 7 days, 30 days, 1 year, and 3 years post-CABG
measure: CV-death
timeFrame: 7 days, 30 days, 1 year, and 3 years post-CABG
measure: Myocardial infraction
timeFrame: 7 days, 30 days, 1 year, and 3 years post-CABG
measure: Stroke
timeFrame: 7 days, 30 days, 1 year, and 3 years post-CABG
measure: Repeat revascularization
timeFrame: 7 days, 30 days, 1 year, and 3 years post-CABG
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin Hospital Shanghai Jiao Tong University School of Medicine
state: Shanghai
Study officials:
affiliation: Ruijin Hospital
name: Qiang Zhao, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Ruijin Hospital
name: Yunpeng Zhu, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Xia T, Li B, Zhang W, Wang Z, Ye X, Zhou M, Li H, Qiu J, Zhu Y, Zhao Q. Risk factors for major adverse cardiovascular events after coronary artery bypass grafting using radial artery grafts. Front Cardiovasc Med. 2023 Sep 27;10:1238161. doi: 10.3389/fcvm.2023.1238161. eCollection 2023.
Clinical trial NCT00945386: The Effect of Continuous, Various Doses of Furosemide Drip on Hearing as Measured by Acoustic Emission
Official title: The Effect of Continuous, Various Dosages of Furosemide Drip on Hearing as Measured by Acoustic Emission
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hearing Status
Keywords: children
critically ill
furosemide
acoustic emission
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2009-07-24
Enrollment: 60
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: critically ill children in pediatric ICU.

Brief summary: Pediatric patients, during their illness often treated with furosemide (Lasix) continuous drip, often, with dosages above 4-6mg/kg/day (the recommended dose).

This study will monitor hearing status of these children prior to their therapy with furosemide, during this therapy and after.

Detailed description: This study will record hearing status, by acoustic emission, of critically ill children, treated with different dosages of furosemide drip.

Acoustic emission test will be done prior to therapy and q48 hours during their course of treatment with furosemide drip.

Dosage of furosemide drip, boluses and other relevant medications (i.e - vancomycin, muscular relaxants, aminoglycosides etc) will be recorded.

Eligibility criteria: Inclusion Criteria:

* All children admitted to Pediatric ICU who are treated with furosemide continuous drip.

Exclusion Criteria:

* Children with known hearing abnormalities prior to treatment.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Petah Tikva
country: Israel
facility: Pediatric ICU, Schneider Children's Hospital
Study officials:
affiliation: Schneider Children's Hospital
name: Elhanan Nahum, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05227586: Adjunctive Right Atrial Ablation for Persistent Atrial Fibrillation With Right Atrial Enlargement
Official title: Adjunctive Right Atrial Ablation for Persistent Atrial Fibrillation With Right Atrial Enlargement
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Persistent Atrial Fibrillation
Right Atrial Enlargement
Keywords: Atrial fibrillation
Right atrium
Lead sponsor: Shanghai Chest Hospital
Sponsor class: OTHER
First posted: 2022-02-07
Enrollment: 195
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population enrolled were patients with persistent atrial fibrillation and right atrial enlargement received catheter ablation for the first time in our institution.

Patients with a history of catheter ablation, valvular heart disease, hypertrophic or dilated cardiomyopathy and unavailable of follow-up data were excluded

Brief summary: This is retrospective cohort study testing whether patients with persistent atrial fibrillation and right atrial enlargement may benefit from adjunctive right atrial ablation.

Detailed description: This is retrospective cohort study testing whether patients with persistent atrial fibrillation and right atrial enlargement may benefit from adjunctive RA ablation.

We enrolled 65 patients with persistent atrial fibrillation and right atrial enlargement received adjunctive right atrial ablation. These patients were 1:2 match with 130 patients received left atrial ablation only. Atrial fibrillation recurrence rate and other paremeters were analyzed to evaluate the efficacy of adjunctive right atrial ablation in this subset of patients.

Eligibility criteria: Inclusion Criteria:

1. Aged 18 to 80 years old;
2. Persistent AF with right atrial enlargement;
3. Nonresponse or intolerance to ≥1 antiarrhythmic drug.

Exclusion Criteria:

1. History of catheter ablation;
2. valvular heart disease;
3. hypertrophic cardiomyopathy or dilated cardiomyopathy;
4. Without follow-up data

Primary outcomes:
measure: atrial fibrillation (AF) recurrence rate
timeFrame: at 12 months post procedure
Secondary outcomes:
measure: atrial fibrillation (AF)/atrial flutter (AFL)/atrial tachycardia (AT) recurrence rate
timeFrame: at 12 months post procedure
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Mu Qin
Study officials:
References:
Clinical trial NCT05356286: Recording of Intraoperative Spinal Cord Stimulation and Monitoring
Official title: Recording of Intraoperative Spinal Cord Stimulation and Monitoring
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cervical Stenosis
Disk, Herniated
Spondylosis
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
First posted: 2022-05-02
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Opioid overdose suppresses brainstem respiratory circuits, causes apnea, and may result in death. Epidural electrical stimulation (EES) at the cervical spinal cord facilitated motor activity in rodents and humans, and we hypothesized that EES of the cervical spinal cord could antagonize opioid-induced respiratory depression in humans. In this study, we will stimulate the spinal cord during surgery and assess its effects on respiratory function in human patients.


Eligibility criteria: Inclusion Criteria:

* Any patients undergoing brain or spinal cord surgery where spinal neuromonitoring is utilized.

Exclusion Criteria:

* none

Primary outcomes:
measure: Change in respiratory frequency
timeFrame: During intraoperative surgery during stimulation and within 2 minutes after stimulation
measure: Change in respiratory tidal volume
timeFrame: During intraoperative surgery during stimulation and within 2 minutes after stimulation
Secondary outcomes:
measure: Change in heart rate
timeFrame: During intraoperative surgery during stimulation and within 2 minutes after stimulation
measure: Change in blood pressure
timeFrame: During intraoperative surgery during stimulation and within 2 minutes after stimulation
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: University of California, Los Angeles
state: California
Study officials:
References:
Clinical trial NCT01968486: Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia
Official title: Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia: 48 Weeks Study Results
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Myopia, Degenerative
Lead sponsor: University of Campania Luigi Vanvitelli
Sponsor class: OTHER
First posted: 2013-10-24
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To demonstrate the efficacy of ranibizumab in combination with reduced-fluence verteporfin photodynamic therapy (RF-PDT) in patients with subfoveal choroidal neovascularization secondary to pathologic myopia (PM).

Detailed description: Sixty patients received ranibizumab 0.5 mg combined with reduced fluence (RF) verteporfin PDT. Ranibizumab was first administered to patients followed after seven days by RF-PDT. Subsequently intravitreal ranibizumab (IVR) was injected as needed (pro re nata). All patients were evaluated every 4 weeks for 48 weeks.

Main Outcome Measures: Mean change in best-corrected visual acuity (BCVA) from baseline at 48 weeks, reduced mean central foveal thickness (CFT) analyzed by optical coherence tomography (OCT) and improved macular sensitivity registered at microperimetry (MP) evaluation.

Eligibility criteria: Inclusion Criteria:

* pathologic myopia, defined as spherical equivalent greater than 6 D and axial length more than 26 mm (Carl Zeiss IOLMaster V 4.07; Carl Zeiss Meditec, Dublin, California, USA);
* posterior pole myopic retinal changes (posterior staphyloma, chorioretinal atrophy, papillary crescent);
* fluorescein angiography (FA) detection of the subfoveal or juxtafoveal CNV (CNV was classified as juxta-foveal if the lesion was closer than 200 mm but not under the geometric center of the foveal avascular zone);
* clear ocular media;
* duration of symptoms no longer than 4 weeks before enrollment.

Exclusion Criteria:

* prior treatment for CNV including previous intravitreal drugs injection or PDT-V;
* presence of other maculopathy as diabetic retinopathy or retinal vascular occlusion;
* history of recent myocardial infarction or other thromboembolic events;
* ongoing uncontrolled hypertension or glaucoma;
* refractive media opacities;
* eye surgery.

Primary outcomes:
measure: Mean change in best-corrected visual acuity (BCVA) from baseline
timeFrame: 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Campania Luigi Vanvitelli
name: Flavia Chiosi, MD
role: PRINCIPAL_INVESTIGATOR
References: